Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib-Reference-Cited by-同舟云学术

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib

Published:2023-07 Issue:7 Volume:34 Page:615-625
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Serrano C.,Bauer S.,Gómez-Peregrina D.,Kang Y.-K.,Jones R.L.,Rutkowski P.,Mir O.,Heinrich M.C.,Tap W.D.,Newberry K.,Grassian A.,Shi H.,Bialick S.,Schöffski P.,Pantaleo M.A.,von Mehren M.,Trent J.C.,George S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference25 articles.

1. Current and future perspectives of liquid biopsies in genomics-driven oncology;Heitzer;Nat Rev Genet,2019

2. Gastrointestinal stromal tumor: challenges and opportunities for a new decade;Serrano;Clin Cancer Res,2020

3. Liquid biopsy in gastrointestinal stromal tumors: ready for prime time?;Gómez-Peregrina;Curr Treat Options Oncol,2021

4. Utility of circulating tumor DNA in the management of patients with GI stromal tumor: analysis of 243 patients;Arshad;JCO Precis Oncol,2020

5. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors;Hirota;Science,1998

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma;Translational Oncology;2024-09

2. Gastrointestinal Stromal Tumors (GISTs) in Pediatric Patients: A Case Report and Literature Review;Children;2024-08-26

3. The potential of lenvatinib in breast cancer therapy;Medical Oncology;2024-08-22

4. Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors;BJC Reports;2024-07-25

5. Reply to Y. Xia et al;Journal of Clinical Oncology;2024-07-08